3 days ago · SALT LAKE CITY—ARUP Laboratories now provides a blood test for phosphorylated tau 217 (pTau 217) to assist in identifying whether cognitive decline symptoms in patients ages 60 years and older are related to Alzheimer's disease (AD) pathology.

Detecting pTau in the blood is now being used as a way to diagnose Alzheimer's disease earlier and more accurately. This research breakthrough is critical because the earlier Alzheimer’s disease is detected, the more potential options for intervention are available.

2 days ago · SALT LAKE CITY — A new blood test used to detect the pathology of Alzheimer’s Disease has just launched in Utah, and local experts are calling it revolutionary. The pTau 217 Blood Test is ...

Plasma P-tau217 and P-tau181 are associated with Alzheimer’s disease (AD) tau pathology. P-tau217 is a more novel blood-based biomarker that may be diagnostically superior to P-tau181.

Discover the benefits of Labcorp's pTau-217/Beta Amyloid 42 Ratio. This new blood test for Alzheimer’s disease aids in the identification of amyloid-related pathology and offers better concordance with amyloid PET imaging than Beta-Amyloid 42/40 Ratio or pTau-217 alone.

Apr 2, 2025 · Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease. BURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau …

Evaluation of individuals, aged 50 years and older, presenting with cognitive impairment who are being assessed for Alzheimer disease and other causes of cognitive decline. This test is not intended as a screening test for Alzheimer disease in asymptomatic individuals. Chemiluminescent Enzyme Immunoassay.